[1] OTT JJ,STEVENTS GA,GROEGER J,et al. Global epidemiology of hepatitis B virus infection:New estimates of agespecific HBsAg seroprevalence and endemicity[J]. Vaccine,2012,30(12):2212-2219.
|
[2] SHEN FF,WANG Y,WANG YF,et al. Prediction of hepatic necroinflammatory activity in patients with chronic hepatitis B by a simple noninvasive model[J]. J Transl Med,2018,16(1):166.
|
[3] ZHU XH,CHEN ZX,ZHUANG X,et al. Comparative effectiveness of prophylactic strategies for perinatal transmission of hepatitis B virus:A network Meta-analysis of randomized controlled tria[J/CD]. Chin J Exp Clin Infect Dis(Electronic Edition),2018,12(4):316-323.(in Chinese)朱晓红,陈智娴,庄勋,等.不同干预措施预防乙型肝炎病毒母婴传播的网络Meta分析[J/CD].中华实验和临床感染病杂志(电子版),2018,12(4):316-323.
|
[4] Chinese Society of Hepatology and Chinese Society of Infectious Diseases Chinese,Medical Association. The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J]. J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.
|
[5] CHENG JL,WANG XL,YANG SG,et al. Non-ALT biomarkers for markedly abnormal liver histology among Chinese persistently normal alanine aminotransferase chronic hepatitis B patients[J]. World J Gastroenterol,2017,23(15):2802-2810.
|
[6] CHAO DT,LIM JK,AYOUB WS,et al. Systematic review with meta-analysis:The proportion of chronic hepatitis B patients with normal alanine transaminase≤40 IU/L and significant hepatic fibrosis[J]. Aliment Pharmacol Ther,2014,39(4):349-358.
|
[7] WU Z,DONG X,WANG G,et al. Clinical noninvasive markers for antiviral therapy decision in chronic hepatitis B with alanine aminotransferase less than two times upper limit of normal[J].J Viral Hepat,2019,26(2):287-296.
|
[8] Chinese Society of Infectious Diseases and Parasitology,Chinese Society of Hepatology, Chinese Medical Association.Prevention and treatment of viral hepatitis[J]. Chin J Infect Dis,2001,19(1):56-62.(in Chinese)中华医学会传染病与寄生虫病学分会,肝病学分会.病毒性肝炎防治方案[J].中华传染病杂志,2001,19(1):56-62.
|
[9] KUMAR M,SARIN SK,HISSAR S,et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT[J]. Gastroenterology,2008,134(5):1376-1384.
|
[10] European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J]. J Hepatol,2017,67(2):370-398.
|
[11] TERRAULT NA,BZOWEJ NH,CHANG KM,et al. AASLD guidelines for treatment of chronic hepatitis B[J]. Hepatology,2016,63(1):261-283.
|
[12] SARIN SK,KUMAR M,LAU GK,et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B:A 2015update[J]. Hepatol Int,2016,10(1):1-98.
|
[13] GUI HL,WANG H,YANG YH,et al. Significant histopathology in Chinese chronic hepatitis B patients with persistently highnormal alanine aminotransferase[J]. J Viral Hepat,2010,17(1):44-50.
|
[14] LIAO B,WANG Z,LIN S,et al. Significant fibrosis is not rare in Chinese chronic hepatitis B patients with persistent normal ALT[J]. PLo S One,2013,8(10):e78672.
|
[15] SETO WK,LAI CL,IP PP,et al. A large population histology study showing the lack of association between ALT elevation and significant fibrosis in chronic hepatitis B[J]. PLo S One,2012,7(2):e32622.
|
[16] SETO WK,WONG DK,FUNQ J,et al. High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B[J]. PLo S One,2012,7(8):e43087.
|
[17] MANSOUR-GHANAEI F,RAFIEI R,JOUKAR F,et al. Relationship between serum HBV DNA level and liver histology in HBV carriers with normal ALT in Guilan province,Iran[J].Med Sci Monit,2010,16(3):br97-br101.
|